RecruitingNot ApplicableNCT05833321

Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

Prospective Monocentric Study of the Detection of Sarcopenia in Clinical Practice in Patients With Ovarian or Endometrial Cancer Requiring Systemic Oncological Treatment


Sponsor

Centre Hospitalier Metropole Savoie

Enrollment

75 participants

Start Date

Nov 20, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological treatment. main question : Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria. Data collection will be done at 6 months, 12 months after the date of inclusion.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria6

  • Patients at least 18 years old
  • Patient presenting with a diagnosis of cancer of ovarian origin with an indication for chemotherapy
  • Patient with a diagnosis of endometrial cancer with an indication for chemotherapy
  • Patient with no diagnosis of other types of cancer in the previous five years
  • Collection of consent
  • Patient affiliated to a Social Security scheme

Exclusion Criteria4

  • Patient with cancer of ovarian origin not requiring chemotherapy treatment
  • Patient with endometrial cancer not requiring chemotherapy treatment
  • Discovery of an intercurrent cancer other than skin or cervix cancers.
  • Patient wearing a Pace maker

Interventions

DIAGNOSTIC_TESTSarcopenia diagnostic test

measurement of impedance and physical tests ("hand grip" dynamometer, walking test), SEFI nutritional intake questionnaire


Locations(1)

Centre Hospitalier Metropole Savoie

Chambéry, Savoie, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05833321


Related Trials